FGFR1 amplification is particularly common, occurring in approximately 20% of non-small cell lung cancers (NSCLC) [1,2] and 7% of urothelial carcinomas, leading to protein overexpression and oncogenic signaling dependency [7]. This evidence concerns the gene FGFR1 and non-small cell lung carcinoma.